With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...

U.S. regulators launch new review of infant RSV therapies from Merck, Sanofi, and AstraZeneca amid scrutiny by Health Secretary Robert F. Kennedy Jr.

Sanofi ( ($SNY) ) just unveiled an update. In December 2025, Sanofi announced the completion of its acquisition of Vicebio Ltd, which enhances its ...

Sanofi (NASDAQ:SNY) is a French pharmaceutical firm that has been at the center of several analysts’ attention lately.

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Indupro Inc. has announced a strategic equity investment and research collaboration with Sanofi SA. The agreement with Sanofi includes the right of first negotiation for Indupro’s bispecific PD-1 ...

Eli Lilly shares rose after the drug giant said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after more than a year of treatment, significantly ...

This stock could be a wealth destroyer in the next five years.

Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

Federal officials say the U.S. Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and ...